Incyte (NASDAQ: INCY) executives outlined a strategy centered on expanding its non-JAKAFI business,

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, ad

CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixe

Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transc

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

Integrated Wealth Concepts LLC trimmed its holdings in Incyte Corporation (NASDAQ: INCY) by 26.0% du

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized ba

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Tra

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise bi

Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-Am

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized ba

Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy ratin

Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises

MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and sup

Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 202

Cetera Investment Advisers trimmed its position in Incyte Corporation (NASDAQ: INCY) by 18.7% in the

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing R

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price t

Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65

Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemoth

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales gro

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance ra

ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to

Incyte (NASDAQ:INCY) reported quarterly earnings of $3.09 per share which beat the analyst consensus

Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billio

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price

Morgan Stanley analyst Judah Frommer maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie